Clinical Impact of New Rheumatoid Arthritis Data from APLAR 2019, JCR 2019, and EULAR 2019*

APLAR 2019: Brisbane, Australia; April 8-11, 2019; JCR: Kyoto, Japan; April 15-17, 2019
EULAR: Madrid, Spain; June 12-15, 2019
Review the latest RA management data with Capsule Summaries, downloadable slides, and expert analysis covering key studies from APLAR 2019, JCR 2019, and EULAR 2019.

Rheumatoid Arthritis

Capsule Summary Slidesets

Withdrawal of csDMARDs had no significant effect on ongoing clinical response compared with continuation of csDMARDs or use of sarilumab monotherapy.

Released: June 27, 2019

IV formulation of prednisolone was more effective than standard IM methylprednisolone for treating RA flares.

Released: July 1, 2019

Add-on therapy with JAK1 inhibitor filgotinib demonstrated improved responses compared with placebo in patients with RA who had inadequate response to methotrexate.

Released: June 18, 2019

Addition of JAK1 inhibitor to methotrexate improved ACR20 responses compared with methotrexate alone in methotrexate-naive patients with RA.

Released: June 27, 2019

Tofacitinib monotherapy after methotrexate withdrawal does not worsen disease activity in RA patients who previously achieved low disease activity with tofacitinib plus methotrexate.

Released: June 18, 2019

Prednisone tapering may be feasible in some RA patients with low disease activity or remission on tocilizumab, although continuous treatment provided superior disease control.

Released: June 19, 2019

SC formulation of CT-P13 demonstrated noninferior efficacy compared to IV formulation for change in DAS28-CRP from baseline to Week 22 in patients with rheumatoid arthritis.

Released: June 21, 2019

Baricitinib demonstrates acceptable safety in RA patients exposed for up to 7 yrs

Released: June 28, 2019

Analysis of pooled data from 5 phase III RCTs in RA patients suggests similarities and differences in safety profile of upadacitinib vs methotrexate or adalimumab.

Released: July 1, 2019

Monotherapy with the investigational JAK1 inhibitor upadacitinib showed sustained clinical improvements and safety outcomes through 48 weeks in patients with RA with inadequate response to methotrexate.

Released: June 24, 2019
Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Gilead Sciences
Lilly
Sanofi Genzyme and Regeneron Pharmaceuticals

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?